A MYC Inhibitor Selectively Alters the MYC and MAX Cistromes and Modulates the Epigenomic Landscape to Regulate Target Gene Expression

MYCi975 synergistically sensitized resistant prostate cancer cells to enzalutamide and estrogen receptor–positive breast cancer cells to 4-hydroxytamoxifen.